272 related articles for article (PubMed ID: 28782483)
1. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
2. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
[TBL] [Abstract][Full Text] [Related]
5. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway.
Yao J; Xu C; Fang Z; Li Y; Liu H; Wang Y; Xu C; Sun Y
Biochem Biophys Res Commun; 2016 May; 474(1):213-219. PubMed ID: 27109471
[TBL] [Abstract][Full Text] [Related]
7. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4.
Draheim KM; Chen HB; Tao Q; Moore N; Roche M; Lyle S
Oncogene; 2010 Sep; 29(36):5032-47. PubMed ID: 20603614
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
9. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
13. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
14. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
16. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
18. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
19. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]